Anal Cancer - Pipeline Review, H2 2014


#238840

54pages

Global Markets Direct

$ 2000

In Stock

Anal Cancer - Pipeline Review, H2 2014

Summary

Global Markets Directs, Anal Cancer - Pipeline Review, H2 2014, provides an overview of the Anal Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Anal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anal Cancer and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Anal Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Anal Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Anal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Anal Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Anal Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Anal Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Anal Cancer Overview 6
Therapeutics Development 7
Pipeline Products for Anal Cancer - Overview 7
Pipeline Products for Anal Cancer - Comparative Analysis 8
Anal Cancer - Therapeutics under Development by Companies 9
Anal Cancer - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Anal Cancer - Products under Development by Companies 12
Anal Cancer - Companies Involved in Therapeutics Development 13
Advaxis, Inc. 13
Amgen Inc. 14
Eli Lilly and Company 15
ISA Pharmaceuticals B.V. 16
MedImmune, LLC 17
THERAVECTYS SA 18
Anal Cancer - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Combination Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
ADXS-HPV - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
durvalumab + tremelimumab - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
ISA-101 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
LY-2606368 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
panitumumab - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Vaccine for HPV Associated Cancers - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Anal Cancer - Recent Pipeline Updates 40
Anal Cancer - Dormant Projects 52
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 54
Disclaimer 54

List of Tables
Number of Products under Development for Anal Cancer, H2 2014 7
Number of Products under Development for Anal Cancer - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Clinical Stage Development, H2 2014 10
Comparative Analysis by Early Stage Development, H2 2014 11
Products under Development by Companies, H2 2014 12
Anal Cancer - Pipeline by Advaxis, Inc., H2 2014 13
Anal Cancer - Pipeline by Amgen Inc., H2 2014 14
Anal Cancer - Pipeline by Eli Lilly and Company, H2 2014 15
Anal Cancer - Pipeline by ISA Pharmaceuticals B.V., H2 2014 16
Anal Cancer - Pipeline by MedImmune, LLC, H2 2014 17
Anal Cancer - Pipeline by THERAVECTYS SA, H2 2014 18
Assessment by Monotherapy Products, H2 2014 19
Assessment by Combination Products, H2 2014 20
Number of Products by Stage and Target, H2 2014 22
Number of Products by Stage and Mechanism of Action, H2 2014 24
Number of Products by Stage and Route of Administration, H2 2014 26
Number of Products by Stage and Molecule Type, H2 2014 28
Anal Cancer Therapeutics - Recent Pipeline Updates, H2 2014 40
Anal Cancer - Dormant Projects, H2 2014 52

List of Figures
Number of Products under Development for Anal Cancer, H2 2014 7
Number of Products under Development for Anal Cancer - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Clinical Stage Development, H2 2014 10
Assessment by Monotherapy Products, H2 2014 19
Number of Products by Top 10 Targets, H2 2014 21
Number of Products by Stage and Top 10 Targets, H2 2014 21
Number of Products by Top 10 Mechanism of Actions, H2 2014 23
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 23
Number of Products by Top 10 Routes of Administration, H2 2014 25
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 25
Number of Products by Top 10 Molecule Types, H2 2014 27
Number of Products by Stage and Top 10 Molecule Types, H2 2014 27